NY Telehealth Extension Advances Rocket Doctor AI Platform

1. Rocket Doctor is a billboard sponsor of Streetwise Reports and pays SWR a monthly sponsorship fee between US$3,000 and US$6,000. 
2. As of the date of this article, officers, contractors, shareholders, and/or employees of Streetwise Reports LLC (including members of their household) own securities of Rocket Doctor.
3. Jordan Nova wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee. 
4.  This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company. 
5. This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

1 Disclosure for the quote from the Stewart Thomson article published on March 17, 2026

1. For the quoted article (published on March 17, Rocket Doctor has paid Street Smart, an affiliate of Streetwise Reports, US$2,500
2. Author Certification and Compensation: Stewart Thomson was retained and compensated as an independent contractor by Street Smart for writing this article. Mr. Thomson is a retired Canadian financial advisor who has passed the Canadian Securities Course as well as additional technical analysis courses that were mandated by his former employer and approved by Ontario regulatory bodies. For the past 15 years, he has been editing and writing numerous financial newsletters that have a strong focus on charts.  The recommendations and opinions expressed in this content reflect the personal, independent, and objective views of the author regarding any and all of the companies discussed. No part of the compensation received by the author was, is, or will be directly or indirectly tied to the specific recommendations or views expressed.

2. Ownership and Share Structure Information

The information listed above was updated on the date this article was published and was compiled from information from the company and various other data providers.

The digital health sector is experiencing rapid expansion driven by telemedicine adoption and artificial intelligence integration, creating opportunities for providers focused on accessible care. Rocket Doctor AI Inc. (AIDR:CSE; AIRDF:OTC; 939:FRA) stands out through its physician-led virtual care model and recent contract extension in New York, positioning the company to capitalize on sustained demand for remote services among underserved populations.

Retail investors evaluating this space should first understand the broader market tailwinds before assessing individual company execution. The global digital transformation in the healthcare market is projected to grow from approximately US$72.3 billion in 2025 to US$81.7 billion in 2026, reaching about US$270.9 billion by 2035 at a compound annual growth rate of 14.13 percent. In neurology specifically, the digital health segment is expected to expand from US$38 billion in 2024 to US$296.3 billion by 2034 at a 22.8 percent CAGR, with North America accounting for more than 39.2 percent of that value.

Why Rocket Doctor AI Stands Out in a Crowded Digital Health Landscape

Rocket Doctor AI differentiates itself through an AI platform designed by physicians to support rather than replace clinical decisions. The technology includes smart triage, remote patient monitoring, multilingual support, and tools that streamline intake, matching, and follow-up workflows. This approach has enabled the company to secure in-network agreements that now cover more than 15 million members across its U.S. payer network.

 Rocket Doctor AI Inc.'s (AIDR:CSE; AIRDF:OTC; 939:FRA) extended its engagement with EngageWell to continue providing physician-led care to underserved communities across New York following completion of the New York Health Foundation-funded "Virtual Pathway to Care" initiative. The recent extension of its engagement with EngageWell builds directly on a successful pilot that connected more than 400 underserved New Yorkers to virtual urgent care, preventive consultations, psychiatric evaluations, and primary care navigation. The renewed arrangement, effective July 1, 2026, runs through October 31, 2029, and blends philanthropic funding with Medicaid reimbursement where appropriate while maintaining no-cost services for uninsured patients.

Key Investor Takeaways

• Rocket Doctor AI has secured a multi-year extension in New York that combines grant support with reimbursement pathways, creating a replicable model for sustainable telehealth delivery.
• The company's AI platform is already integrated with payer contracts covering more than 15 million members and more than 350 physicians, giving it a competitive lead estimated at 18 to 24 months over potential entrants.
• Expansion priorities include Florida and Texas alongside continued AI product development through pharmacy kiosks, Voice AI, and licensing of the Global Library of Medicine API.
• Analyst Stewart Thomson assigned a Strong Speculative Buy rating with technical price targets of CA$0.80 short-term, CA$1.00 medium-term, and CA$1.60 long-term.¹
• The broader digital health market is growing at double-digit CAGRs, supported by specialist shortages and increasing acceptance of remote care among older adults.

Unique Business Model and Competitive Advantages

Rocket Doctor's platform centers on enhancing provider capabilities across specialties. Key components include AI-supported clinical workflows, patient intake and triage, physician matching, and remote monitoring. The company has also developed the Global Library of Medicine (GLM) API, which draws on more than 25,000 clinician hours and covers over 1,000 diseases and 17,000 symptoms.

This infrastructure supports both direct patient care and third-party licensing opportunities. In addition to the New York partnership, Rocket Doctor operates a Healthy Aging program funded by the CVS Health Foundation that targets 750 mental health assessments, 750 cognitive assessments, and 750 heart health consultations for adults aged 60 and older, all provided at no cost through October 31, 2029.

Industry Timing and Growth Catalysts

Market reports highlight persistent digital skills gaps in healthcare and a global neurologist density of just 0.43 per 100,000 adults, factors that favor scalable telehealth solutions. Rocket Doctor is scheduled to participate in Canada's ALL IN 2026 AI conference in Montreal on September 16-17, 2026, where updates on technology and commercialization may be shared. Near-term priorities also include advancing the commercialization of AI products and identifying additional state markets for expansion.

Analyst Views, Valuation Considerations, and Share Structure

¹In a March 17 report, technical analyst Stewart Thomson assigned Rocket Doctor AI Inc. a Strong Speculative Buy technical rating, citing the company's technology, payer contracts, and credentialing as difficult for competitors to replicate quickly. He noted that 37 percent of U.S. adults had used telemedicine by 2021, with higher adoption among those aged 65 and older.

Rocket Doctor AI has 99.16 million shares outstanding and a market capitalization of CA$59.50 million. Insider ownership stands at 4.29 percent, with retail investors holding the balance. The 52-week trading range is CA$0.33 to CA$0.98 per share.

Common Questions from Investors

What is the duration of the renewed EngageWell engagement?

The extended agreement took effect July 1, 2026, and aligns with grant-funded initiatives through October 31, 2029, allowing continued delivery of no-cost telemedicine to uninsured New Yorkers while exploring Medicaid reimbursement pathways.

Which states are targeted for future U.S. expansion?

Rocket Doctor has identified Florida and Texas as priority markets, building on existing operations in New York, California, and Maryland.

How does the company plan to commercialize its AI technology?

Plans include pharmacy kiosks, Voice AI applications, and third-party licensing of the Global Library of Medicine API in addition to ongoing platform enhancements.

What market growth rates support the digital health thesis?

Healthcare Foresights projects the broader digital transformation market to reach approximately US$270.9 billion by 2035 at a 14.13 percent CAGR, while the neurology-focused digital health segment is expected to reach US$296.3 billion by 2034 at a 22.8 percent CAGR.

Investors should weigh execution risks typical of early-stage healthcare technology companies against the demonstrated pilot results and multi-year partnership visibility. The combination of grant-backed community programs and expanding payer relationships provides a foundation for scaling, provided reimbursement pathways continue to develop.